Deerfield Management Company, L.P. 的 Form 4 申報
ARS Pharmaceuticals, Inc.（SPRY），2024/11/13 申報
- 申報編號
- 0001193805-24-001348
- 申報時間
- 2024/11/13 20:16 ET
- 交易日
- 2024/11/11-11/12
- 申報延遲
- 2 天
- 10b5-1 計畫
- 沒有勾選
這份申報列了 8 筆非衍生性交易。公開市場賣出合計 $1,014 萬。交易後 2 天申報。
申報人
一份 Form 4 可以有好幾位申報人，例如本人與他控制的基金。各交易表上顯示的是第一位。
| 申報人 | 與公司的關係 |
|---|---|
| Deerfield Management Company, L.P.CIK 0001009258 | 持股 10% 以上大股東 |
| Flynn James ECIK 0001352546 | 持股 10% 以上大股東 |
| Deerfield Private Design Fund III, L.P.CIK 0001603333 | 持股 10% 以上大股東 |
| Deerfield Mgmt III, L.P.CIK 0001610540 | 持股 10% 以上大股東 |
| Deerfield Private Design Fund IV, L.P.CIK 0001680307 | 持股 10% 以上大股東 |
| Deerfield Mgmt IV, L.P.CIK 0001713467 | 持股 10% 以上大股東 |
非衍生性證券（表 I）
普通股等股票的取得與處分，每一列是申報上的一筆。
| 交易日 | 證券 | 交易 | 股數 | 價格 | 金額 | 交易後持股 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2024/11/11 | Class A Common Stock | S賣出處分 | −40,596 | $17.45F1 | −$708,400.2 | 5,498,368 | 間接 | |
| 2024/11/11 | Class A Common Stock | S賣出處分 | −40,596 | $17.45F1 | −$708,400.2 | 5,498,367 | 間接 | |
| 2024/11/11 | Class A Common Stock | S賣出處分 | −223,632 | $18.15F4 | −$4,058,920.8 | 5,274,736 | 間接 | |
| 2024/11/11 | Class A Common Stock | S賣出處分 | −223,632 | $18.15F4 | −$4,058,920.8 | 5,274,735 | 間接 | |
| 2024/11/12 | Class A Common Stock | S賣出處分 | −7,853 | $17.16F5 | −$134,757.48 | 5,266,883 | 間接 | |
| 2024/11/12 | Class A Common Stock | S賣出處分 | −7,854 | $17.16F5 | −$134,774.64 | 5,266,881 | 間接 | |
| 2024/11/12 | Class A Common Stock | S賣出處分 | −9,554 | $17.77F6 | −$169,774.58 | 5,257,329 | 間接 | |
| 2024/11/12 | Class A Common Stock | S賣出處分 | −9,553 | $17.77F6 | −$169,756.81 | 5,257,328 | 間接 |
附註與備註
本站收錄交易價格引用的附註、修正申報（Form 4/A）的全部附註，以及申報的備註。其他附註，例如間接持有的方式、交易計畫的細節，請看 SEC EDGAR 上的原文。
- F1
The price reported in Column 4 represents a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.90 to $17.90, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 1, 4, 5 and 6 of this Form 4.
表 I 有 2 筆交易的價格引用這則附註。
- F4
The price reported in Column 4 represents a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.91 to $18.51, inclusive.
表 I 有 2 筆交易的價格引用這則附註。
- F5
The price reported in Column 4 represents a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.68 to $17.65, inclusive.
表 I 有 2 筆交易的價格引用這則附註。
- F6
The price reported in Column 4 represents a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.69 to $17.82, inclusive.
表 I 有 2 筆交易的價格引用這則附註。
備註
Jonathan Isler, Attorney-in-Fact: Power of Attorney, which is hereby incorporated by reference to Exhibit 24 to a Form 3 with regard to BiomX Inc. filed with the Securities and Exchange Commission on March 19, 2024 by Deerfield Private Design Fund III, L.P., Deerfield Private Design Fund IV, L.P., Deerfield Mgmt III, L.P., Deerfield Mgmt IV, L.P., Deerfield Management Company, L.P. and James E. Flynn.